ReviewOpen forum infectious diseases2022
A Systematic Review of COVID-19 Vaccine Antibody Responses in People With HIV.
Review in Open forum infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Immunogenicity and safety of the booster COVID-19 vaccine among people with HIV: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Mortality trends for diabetes mellitus, hypertension and cardiovascular disease among people living with and without HIV in Brazil during the COVID-19 pandemic, 2020-2022.HIV medicine · 2026Article
- Seroconversion Rates Following COVID-19 Vaccination in People Living with HIV: A Systematic Review and Meta-Analysis.Vaccines · 2026Review
- High risk of COVID-19 mortality in people living with advanced HIV disease in South Africa: A retrospective cohort study.Medicine · 2026Article
- SARS-CoV-2 Infection and COVID-19 Vaccine Antibody Responses in Two Canadian Cohorts of Persons Living with HIV.Antibodies (Basel, Switzerland) · 2026Article
- Epidemiological and economic impact of pre-exposure prophylaxis with targeted immunotherapies for COVID-19 among immunosuppressed patients in Argentina.Cost effectiveness and resource allocation : C/E · 2026Article
- Leveraging remnant viral load samples for SARS-CoV-2 antibody seroprevalence trends among PLHIV in Kenya, February 2021-October 2022: a cross-sectional surveillance survey.BMJ public health · 2026Article
- COVID-19 mortality among people living with HIV/AIDS in Brazil: a multilevel analysis.AIDS research and therapy · 2025Article
- A cross-section study of the relationship between lifestyles and severity of COVID-19 symptoms in people living with HIV.Scientific reports · 2025Article
- Differential immunogenicity in people living with HIV with varying CD4 levels after bivalent mRNA COVID-19 booster vaccination.PloS one · 2025Article
- Relationships Among COVID-19-Related Service Uptake, HIV Status, Drug Use, and COVID-19 Antibody Status Among HIV Testing Intervention Participants in KwaZulu-Natal, South Africa.International journal of environmental research and public health · 2024Article
- Breakthrough COVID-19 Infections after Booster SARS-CoV-2 Vaccination in a Greek Cohort of People Living with HIV during the Delta and Omicron Waves.Biomedicines · 2024Article
- Article
- Correlates of Breakthrough SARS-CoV-2 Infections in People with HIV: Results from the CIHR CTN 328 Study.Vaccines · 2024Article
- Factors associated with SARS-CoV-2 infection among people living with HIV: Data from the Balearic cohort (EVHIA).PloS one · 2024Article
- The Interrelationship between HIV Infection and COVID-19: A Review of the Literature.Current HIV research · 2024Review
- Triple Burden: The Incorrigible Threat of Tuberculosis, HIV, and COVID-19.Infectious disorders drug targets · 2024Review
- Characterization of Immunogenicity and Safety of COVID-19 mRNA-1273 in HIV-Positive Italian Patients with Hemophilia: A Prospective Single-Center Cohort Study.Journal of clinical medicine · 2023Article
- Effectiveness and Safety of SARS-CoV-2 Vaccination in HIV-Infected Patients-Real-World Study.Vaccines · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
HIV infection is a significant independent risk factor for severe coronavirus disease 2019 (COVID-19) disease and death. We summarize COVID-19 vaccine responses in people with HIV (PWH). A systematic literature review of studies from January 1, 2020, to March 31, 2022, of COVID-19 vaccine immunogenicity in PWH from multiple databases was performed. Twenty-eight studies from 12 countries were reviewed. While 22 (73%) studies reported high COVID-19 vaccine seroconversion rates in PWH, PWH with lower baseline CD4 counts, CD4/CD8 ratios, or higher baseline viral loads had lower seroconversion rates and immunologic titers. Data on vaccine-induced seroconversion in PWH are reassuring, but more research is needed to evaluate the durability of COVID-19 vaccine responses in PWH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.